Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 21
2003 28
2004 19
2005 23
2006 12
2007 16
2008 8
2009 13
2010 7
2011 8
2012 4
2013 3
2014 4
2015 3
2016 5
2017 7
2018 2
2019 3
2020 6
2021 6
2022 2
2023 2
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.
Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC. Gulla A, et al. Among authors: chauhan d. Blood Cancer Discov. 2021 Sep;2(5):468-483. doi: 10.1158/2643-3230.BCD-21-0047. Epub 2021 Apr 23. Blood Cancer Discov. 2021. PMID: 34568832 Free PMC article.
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.
Du T, Song Y, Ray A, Wan X, Yao Y, Samur MK, Shen C, Penailillo J, Sewastianik T, Tai YT, Fulciniti M, Munshi NC, Wu H, Carrasco RD, Chauhan D, Anderson KC. Du T, et al. Among authors: chauhan d. Blood. 2023 May 25;141(21):2599-2614. doi: 10.1182/blood.2022017897. Blood. 2023. PMID: 36630605
A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth.
Morelli E, Fulciniti M, Samur MK, Ribeiro CF, Wert-Lamas L, Henninger JE, Gullà A, Aktas-Samur A, Todoerti K, Talluri S, Park WD, Federico C, Scionti F, Amodio N, Bianchi G, Johnstone M, Liu N, Gramegna D, Maisano D, Russo NA, Lin C, Tai YT, Neri A, Chauhan D, Hideshima T, Shammas MA, Tassone P, Gryaznov S, Young RA, Anderson KC, Novina CD, Loda M, Munshi NC. Morelli E, et al. Among authors: chauhan d. Blood. 2023 Jan 26;141(4):391-405. doi: 10.1182/blood.2022016892. Blood. 2023. PMID: 36126301 Free PMC article.
A 3D-Bioprinted Multiple Myeloma Model.
Wu D, Wang Z, Li J, Song Y, Perez MEM, Wang Z, Cao X, Cao C, Maharjan S, Anderson KC, Chauhan D, Zhang YS. Wu D, et al. Among authors: chauhan d. Adv Healthc Mater. 2022 Apr;11(7):e2100884. doi: 10.1002/adhm.202100884. Epub 2021 Sep 23. Adv Healthc Mater. 2022. PMID: 34558232 Free PMC article.
The power of proteasome inhibition in multiple myeloma.
Guerrero-Garcia TA, Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Mitsiades C, Anderson KC, Richardson PG. Guerrero-Garcia TA, et al. Among authors: chauhan d. Expert Rev Proteomics. 2018 Dec;15(12):1033-1052. doi: 10.1080/14789450.2018.1543595. Epub 2018 Nov 14. Expert Rev Proteomics. 2018. PMID: 30427223 Review.
New proteasome inhibitors in myeloma.
Lawasut P, Chauhan D, Laubach J, Hayes C, Fabre C, Maglio M, Mitsiades C, Hideshima T, Anderson KC, Richardson PG. Lawasut P, et al. Among authors: chauhan d. Curr Hematol Malig Rep. 2012 Dec;7(4):258-66. doi: 10.1007/s11899-012-0141-2. Curr Hematol Malig Rep. 2012. PMID: 23065395 Review.
The proteasome and proteasome inhibitors in multiple myeloma.
Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. Gandolfi S, et al. Among authors: chauhan d. Cancer Metastasis Rev. 2017 Dec;36(4):561-584. doi: 10.1007/s10555-017-9707-8. Cancer Metastasis Rev. 2017. PMID: 29196868 Review.
Cytokines and signal transduction.
Hideshima T, Podar K, Chauhan D, Anderson KC. Hideshima T, et al. Among authors: chauhan d. Best Pract Res Clin Haematol. 2005;18(4):509-24. doi: 10.1016/j.beha.2005.01.003. Best Pract Res Clin Haematol. 2005. PMID: 16026734 Review.
Melflufen - a peptidase-potentiated alkylating agent in clinical trials.
Wickström M, Nygren P, Larsson R, Harmenberg J, Lindberg J, Sjöberg P, Jerling M, Lehmann F, Richardson P, Anderson K, Chauhan D, Gullbo J. Wickström M, et al. Among authors: chauhan d. Oncotarget. 2017 Jun 8;8(39):66641-66655. doi: 10.18632/oncotarget.18420. eCollection 2017 Sep 12. Oncotarget. 2017. PMID: 29029544 Free PMC article. Review.
Novel targeted agents in the treatment of multiple myeloma.
Varga C, Laubach J, Hideshima T, Chauhan D, Anderson KC, Richardson PG. Varga C, et al. Among authors: chauhan d. Hematol Oncol Clin North Am. 2014 Oct;28(5):903-25. doi: 10.1016/j.hoc.2014.07.001. Epub 2014 Aug 5. Hematol Oncol Clin North Am. 2014. PMID: 25212889 Review.
183 results